Award
NIH Reporter #5U54CA274321-05
Quantification of cisplatin sensitivity and resistance using metabolic imaging and circulating tumor cell (CTC) biomarkers
Recipient
University of TX MD Anderson Cancer Center
Award Amount
$232,073.00
Ceiling
$232,073.00
Awarded
September 08, 2026
Identifier
5U54CA274321-05
NIH awarded $232,073 to University of TX MD Anderson Cancer Center for research on using HP-MRI and CTC biomarkers to predict cisplatin sensitivity and resistance in cancer treatment, aiming to improve precision oncology.
Description
This project focuses on assessing tumor response with minimally invasive imaging (hyperpolarized magnetic resonance imaging; HP-MRI) and detection of biological shifts in circulating tumor cells (CTCs) during cisplatin-based therapy to validate biomarkers and optimize treatment for head and neck squamous cell carcinoma (HNSCC).